XML 157 R106.htm IDEA: XBRL DOCUMENT v3.23.4
Subsequent Events - Additional Information (Details) - $ / shares
Sep. 29, 2023
Sep. 08, 2023
Jul. 07, 2023
Jun. 22, 2023
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsequent Event [Line Items]              
Common stock, par value         $ 0.0001 $ 0.0001 $ 0.0001
Stockholders' equity, reverse stock split   1-for-25          
Reduction in the total number of authorized shares   25          
Parapyre Option Obligation              
Subsequent Event [Line Items]              
Share-based payment award, term 10 years            
Spyre Therapeutics, Inc. | Common Stock              
Subsequent Event [Line Items]              
Number of shares transferred as equity interest in asset acquisition       517,809      
Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock              
Subsequent Event [Line Items]              
Number of shares transferred as equity interest in asset acquisition       364,887      
Subsequent Event              
Subsequent Event [Line Items]              
Common stock, par value   $ 0.0001          
Stockholders' equity, reverse stock split   1-for-25          
Subsequent Event | Parapyre Option Obligation              
Subsequent Event [Line Items]              
Share-based payment award, term 10 years            
Subsequent Event | Maximum              
Subsequent Event [Line Items]              
Reduction in the total number of authorized shares   500,000,000          
Subsequent Event | Minimum              
Subsequent Event [Line Items]              
Reduction in the total number of authorized shares   20,000,000          
Subsequent Event | Spyre Therapeutics, Inc. | Common Stock              
Subsequent Event [Line Items]              
Number of shares transferred as equity interest in asset acquisition     517,809        
Subsequent Event | Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock              
Subsequent Event [Line Items]              
Number of shares transferred as equity interest in asset acquisition     364,887